Similarly, the American Heart Association in 2017 also recommended that in heart failure patients with NYHA class II and III, and iron deficiency (ferritin <100 ng/mL or 100 to 300 ng/mL if transferrin saturation is <20%), intravenous iron replacement might be reasonable to improve functional status and QoL [59]. This evidence concerns the gene TF and heart failure.